Disease Overview：Triple-Negative Breast Cancer（TNBC）
Triple-negative breast cancer (TNBC) is an aggressive subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression—rendering it unresponsive to hormonal therapies or HER2-targeted agents. Comprising approximately 10–15% of all breast cancers, TNBC disproportionately affects younger women and those of African or Hispanic descent, with higher rates of early recurrence, distant metastasis (particularly to lung, brain, and liver), and poorer overall survival compared to other subtypes. Diagnosis relies on immunohistochemistry (IHC) and confirmatory testing; treatment hinges on multimodal strategies including neoadjuvant or adjuvant chemotherapy (e.g., anthracycline/taxane-based regimens), surgical resection (lumpectomy or mastectomy), radiation, and increasingly, immunotherapy (e.g., pembrolizumab combined with chemotherapy for PD-L1–positive cases) and PARP inhibitors for BRCA-mutated patients.
China offers compelling advantages for TNBC management: leading oncology centers—such as Fudan University Shanghai Cancer Center and Sun Yat-sen University Cancer Center—maintain internationally accredited tumor boards, extensive clinical trial portfolios (including phase III studies in antibody-drug conjugates like sacituzumab govitecan), and rapid access to next-generation sequencing and liquid biopsy platforms. Five-year survival rates for early-stage TNBC treated at top-tier institutions align closely with U.S. and European benchmarks, supported by robust real-world outcome data. Crucially, comprehensive care—including genomic profiling, surgery, radiotherapy, and targeted biologics—is typically delivered at 40–60% lower cost than in the U.S. or Western Europe, without compromising quality or regulatory oversight (NMPA-approved therapeutics, ISO-certified facilities). As a dedicated medical tourism agency, we facilitate seamless international patient journeys: verifying hospital credentials, coordinating appointments with TNBC-specialized oncologists, providing itemized, transparent pricing in advance, arranging visa support, interpreters, and post-treatment follow-up—all tailored to address concerns about efficacy, safety, and financial predictability.
Triple-Negative Breast Cancer: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Triple-Negative Breast Cancer (TNBC)
Non-Surgical/Medical Therapies
*Eligibility*: Confirmed TNBC (ER/PR/HER2-negative) by IHC/FISH; stage I–IV; adequate organ function (LVEF ≥50%, ANC ≥1.5×10⁹/L, creatinine clearance ≥60 mL/min).
- •Neoadjuvant Chemotherapy (Standard for Stage II–III):
- *Drug cost*: $1,280–$1,920 (paclitaxel: $320–$480/dose × 12; carboplatin: $720–$1,080/dose × 4) - *Supportive care*: G-CSF ($120–$180/dose × 2–4), antiemetics ($25–$45/dose × 12) - *Monitoring*: CBC/chemistry weekly ($18–$28/test), cardiac echo pre-cycle 1 ($110), CT chest/abdomen/pelvis pre/post ($220–$330)
- •Adjuvant Immunotherapy (PD-L1+ tumors, stage II–III):
- *Drug cost*: $2,880–$3,600 ($320–$400/dose) - *Biomarker testing*: PD-L1 IHC (SP142 assay) — $180
- •Metastatic Setting (1st-line):
- *Sacituzumab govitecan*: $4,800–$6,000 (10 mg/kg IV q2w × 4 cycles; $1,200–$1,500/dose)
Surgical/Procedural Interventions
*Eligibility*: Clinically resectable disease (cT1–4, N0–2, M0); ECOG 0–2; no contraindications to anesthesia.
- •Breast-Conserving Surgery (BCS) + Sentinel Lymph Node Biopsy (SLNB):
- *Pre-op workup*: Mammogram + ultrasound ($180), MRI ($360), core biopsy ($120), SLN mapping (Tc-99m + blue dye, $240)
- •Modified Radical Mastectomy (MRM):
- *Pre-op workup*: Same as BCS + chest wall CT ($220) if high-risk features
- •Axillary Lymph Node Dissection (ALND):
Special/Complex Scenarios
- •BRCA1/2 Mutation Carriers:
- *PARP inhibitor (olaparib)*: $2,400–$3,000/month (maintenance after platinum chemo)
- •Brain Metastases:
- *Stereotactic radiosurgery (SRS)*: $2,880–$4,320 (single fraction)
Quick Selection Guide
- •Early-stage (I–II), <65 y, no comorbidities: BCS + SLNB ($2,160–$2,880) → neoadjuvant chemo ($1,280–$1,920) → adjuvant pembrolizumab if PD-L1+ ($2,880–$3,600). *Total estimated*: $6,320–$8,400.
- •Locally advanced (III), BRCA+: Neoadjuvant chemo + immunotherapy → MRM + ALND ($2,880–$3,600 + $960–$1,200) → olaparib maintenance ($2,400–$3,000/month). *Initial procedural cost*: $3,840–$4,800.
- •Metastatic, budget-constrained (<$3,000): Gemcitabine/carboplatin ($1,440–$2,160) + supportive care. Avoid sacituzumab unless progression on chemo.
- •Elderly (>75 y) or frail (ECOG ≥3): Palliative single-agent capecitabine ($480–$720/course) + symptom management. Pre-op labs only ($180–$240).
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Triple-Negative Breast Cancer Medical Vacation Packages
Curated transparent all-inclusive packages combining Triple-Negative Breast Cancer treatment with China top medical destinations:
